Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Atrium Therapeutics, Inc.NASDAQ: RNA
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow of -$33.24M in Q1 FY2026
Q1 FY2026 free cash flow was -$33.24M.
Context
- Free cash flow amounted to 228.7% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (42.57M) USD
- Year-over-year change
- —
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (42.57M) | — |
Free Cash Flow vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Free Cash Flow figures are available to compare.
Cash Flow Statement
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.